Nasdaq:US$42.05 (+1.07) | HKEX:HK$70.60 (-7.00) | AIM:£5.95 (+0.03)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2012-06-01

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors